Rhythm touts Phase 3 win for rare obe­si­ty drug in peo­ple with brain dam­age

Rhythm Phar­ma­ceu­ti­cals is look­ing to ex­pand the po­ten­tial mar­ket for its rare obe­si­ty treat­ment Im­civree be­yond ge­net­ic dis­or­ders.

The com­pa­ny said Mon­day the med­i­cine re­duced …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER